Acceptance of the drug application by the NMPA marks an essential step in introducing NVK002 as a potential therapeutic option for managing myopia in children across China. “NMPA acceptance of ...

Currently valued at approximately KRW 500 billion, the company is poised for a new leap forward with the NMPA approval. CEO Hwan-Chul Lee stated, “Stock prices reflect a company’s growth and stability ...

Based on the results of the FLAMES study, the National Medicines Products Administration (NMPA) has approved the new drug application for Senaparib. The Wee1 inhibitor IMP7068 and the ATR ...

A separate NDA for the first-line treatment in adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations is currently under NMPA review.

NMPA Breakthrough Therapy Designation is intended to facilitate and expedite the development and review of investigational drugs for serious diseases or conditions when preliminary clinical evidence ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...

The NMPA has also converted the prior conditional approval of ORPATHYS ® in the previously treated patient population to full approval. The new label indication for ORPATHYS ® will now include both ...

Chinese biopharma Hutchmed (LON: HCM) today announced that the supplemental New Drug Application for Orpathys (savolitinib) has been granted approval by the China National Medical Products ...

Based on the results of the FLAMES study, the National Medicines Products Administration (NMPA) has approved the new drug application for Senaparib. The Wee1 inhibitor IMP7068 and the ATR inhibitor ...